Erratum to ‘Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma’ [Eur J Cancer 170 (2022) 209-235]

Axel Budde(University Hospital Bonn), Matthias Schmid(Zimmer Biomet (Netherlands)), Stefan Bielack(Olgahospital), Catharina Dhooge(Ghent University Hospital), Jeremy Whelan(University College London Hospitals NHS Foundation Trust), Mark Bernstein(University of Alabama at Birmingham), Katherine A. Janeway(Harvard University), Lars Hjorth(Lund University), Matthew R. Sydes(MRC Clinical Trials Unit at UCL), Meriel Jenney(Noah's Ark Children's Hospital for Wales), Patricia De Vos(Ghent University Hospital), Katja Baust(University Hospital Bonn), Andreas Wiener, Sigbjørn Smeland(Oslo University Hospital), Neyssa Marina(Coherus BioSciences (United States)), Rajaram Nagarajan(University of Minnesota), Leonie Weinhold(University Hospital Bonn), Mark Krailo(Arcadia), Gabriele Calaminus(University Hospital Bonn)
European Journal of Cancer
November 5, 2022
10.1016/j.ejca.2022.06.053
Cited by 0

Related Papers

Chronic Health Conditions in Adult Survivors of Childhood Cancer
|New England Journal of Medicine|2006|3.6k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k